NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-09-15Est. Completion: 2029-04-30

Enrollment target: 86 participants

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Contact

Genevieve C FrommNCICAR@mail.nih.gov (240) 858-3663

James N Kochenderfer, M.D.kochendj@mail.nih.gov (240) 760-6062

Other microbiome trials you might be interested in

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Phase 2Recruiting

Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia, Myelodysplasia-RelatedMyelodysplastic Syndrome

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific lab…

Birmingham, United StatesEst. completion May 15, 2029

View Trial →

Natural History Study of Early Life Exposures in Agriculture (ELEA)ENROLLING_BY_INVITATION

Prostate CancerLeukemiaBreast Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.